LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

Начало・Списък с акции・Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals Inc

Затворен

СекторЗдравеопазване

21.68 1.74

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

20.5

Максимум

21.82

Ключови измерители
By Trading Economics
Приходи	11M -61M
Продажби	7.9M 46M
Марж на печалбата	-132.36
Служители	270
EBITDA	6.3M -58M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+82.68% upside

Дивиденти
By Dow Jones
Следващи печалби	2.03.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	712M 1.8B
Предишно отваряне	19.94
Предишно затваряне	21.68

Настроения в новините

By Acuity

24%

76%

48 / 352 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

9.91 / 14.15 Подкрепа & съпротива

Syndax Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

10.02.2026 г., 23:26 ч. UTC

Значими двигатели на пазара

Moderna Stock Slips After FDA Refuses Flu Vaccine Review

10.02.2026 г., 22:31 ч. UTC

Печалби

Correction to America Movil 4Q Profit Article

10.02.2026 г., 22:22 ч. UTC

Печалби

America Movil 4Q Profit Jumps on Lower Financial Costs

10.02.2026 г., 23:51 ч. UTC

Пазарно говорене

Печалби

Commonwealth Bank's Margin Management Gives It a Platform -- Market Talk

10.02.2026 г., 23:42 ч. UTC

Пазарно говорене

Gold Rises Amid Fed Rate-Cut Prospects -- Market Talk

10.02.2026 г., 23:40 ч. UTC

Пазарно говорене

Печалби

Commonwealth Bank Bear Says 1H Result Looks Strong -- Market Talk

10.02.2026 г., 23:21 ч. UTC

Пазарно говорене

Ford Says EV Shift Was Driven by Demand Changes -- Market Talk

10.02.2026 г., 23:21 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

10.02.2026 г., 22:17 ч. UTC

Пазарно говорене

Australia's One Nation Now Commands Working Class Vote -- Market Talk

10.02.2026 г., 22:15 ч. UTC

Печалби

Humana Earnings Will Shed More Light on Medicare Prospects -- Barrons.com

10.02.2026 г., 22:10 ч. UTC

Печалби

Intact Financial 4Q Book Value Per Share Was C$107.35 >IFC.T

10.02.2026 г., 22:10 ч. UTC

Печалби

Intact Financial Raises Qtr Dividend to C$1.47 >IFC.T

10.02.2026 г., 22:09 ч. UTC

Печалби

Intact Financial 4Q Combined Ratio Was 85.9% >IFC.T

10.02.2026 г., 22:09 ч. UTC

Печалби

Intact Financial 4Q Adj EPS C$5.50 >IFC.T

10.02.2026 г., 22:01 ч. UTC

Печалби

Intact Financial 4Q EPS C$5.24 >IFC.T

10.02.2026 г., 21:54 ч. UTC

Печалби

James Hardie Industries Sees FY26 Total Adjusted EBITDA $1.232B to $1.263B >JHX

10.02.2026 г., 21:53 ч. UTC

Печалби

Robinhood Stock Tumbles as Crypto-Related Revenue Falls Short of Expectations -- Barrons.com

10.02.2026 г., 21:51 ч. UTC

Печалби

James Hardie Industries Sees FY26 Free Cash Flow at Least $200M

10.02.2026 г., 21:51 ч. UTC

Печалби

Gilead Earnings Surprise. Why The Stock Is Tumbling Anyway. -- Barrons.com

10.02.2026 г., 21:51 ч. UTC

Печалби

James Hardie Industries: Focused on the Achievement of $125 M Target >JHX

10.02.2026 г., 21:51 ч. UTC

Печалби

James Hardie Industries: Integration and Cost Synergies Ahead of Schedule >JHX

10.02.2026 г., 21:51 ч. UTC

Печалби

Придобивния, сливания и поглъщания

Evolution Net Debt A$362 Million at Dec. 31 Vs A$1.29 Billion Year Earlier

10.02.2026 г., 21:50 ч. UTC

Печалби

Придобивния, сливания и поглъщания

Evolution: Gearing 6% at Dec. 31, From 23% a Year Earlier

10.02.2026 г., 21:50 ч. UTC

Печалби

James Hardie Industries 3Q EPS 12c >JHX

10.02.2026 г., 21:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

10.02.2026 г., 21:50 ч. UTC

Печалби

James Hardie Industries 3Q Adj EPS 24c >JHX

10.02.2026 г., 21:49 ч. UTC

Печалби

James Hardie Industries 3Q Sales $1.24B >JHX

10.02.2026 г., 21:49 ч. UTC

Печалби

Придобивния, сливания и поглъщания

Evolution 1H Operating Mine Cash Flow a Record A$1.73 Billion

10.02.2026 г., 21:48 ч. UTC

Печалби

Придобивния, сливания и поглъщания

Evolution 1H Ebitda A$1.56 Billion, Up 59% On-Year

10.02.2026 г., 21:47 ч. UTC

Печалби

Придобивния, сливания и поглъщания

Evolution 1H Revenue A$2.79 Billion, Up 37% On-Year

Сравнение с други в отрасъла

Ценова промяна

Syndax Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

82.68% нагоре

12-месечна прогноза

Среден 38.71 USD 82.68%

Висок 56 USD

Нисък 28 USD

Според 8 анализатори от Wall Street, предложили 12-месечна ценова цел за Syndax Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

8 ratings

Купи

Задържане

Продай

Според 8 анализатори, дали борсови рейтинги на Syndax Pharmaceuticals Inc през последните 3 месеца.

Техническа оценка

By Trading Central

9.91 / 14.15Подкрепа & съпротива

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

There is one bearish event.

Настроение

By Acuity

48 / 352 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.